Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

DMK

DMK Pharmaceuticals (DMK)

DMK Pharmaceuticals Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DMK
DatumZeitQuelleÜberschriftSymbolFirma
21/03/202419h23Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:DMKDMK Pharmaceuticals Corporation
07/02/202423h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
06/02/202416h04Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DMKDMK Pharmaceuticals Corporation
05/02/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
31/01/202423h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
23/01/202423h23Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DMKDMK Pharmaceuticals Corporation
23/01/202423h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
03/01/202423h03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DMKDMK Pharmaceuticals Corporation
03/01/202423h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
03/01/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
21/12/202318h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
21/12/202314h15GlobeNewswire Inc.DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHINASDAQ:DMKDMK Pharmaceuticals Corporation
04/12/202322h47Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DMKDMK Pharmaceuticals Corporation
04/12/202322h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
28/11/202322h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
28/11/202314h05GlobeNewswire Inc.DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate UpdateNASDAQ:DMKDMK Pharmaceuticals Corporation
15/11/202322h39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DMKDMK Pharmaceuticals Corporation
15/11/202322h20Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DMKDMK Pharmaceuticals Corporation
15/11/202322h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
15/11/202322h06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DMKDMK Pharmaceuticals Corporation
14/11/202321h57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
14/11/202313h30GlobeNewswire Inc.DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:DMKDMK Pharmaceuticals Corporation
13/11/202316h52GlobeNewswire Inc.DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023NASDAQ:DMKDMK Pharmaceuticals Corporation
02/11/202321h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMKDMK Pharmaceuticals Corporation
02/11/202321h31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DMKDMK Pharmaceuticals Corporation
30/10/202312h30GlobeNewswire Inc.DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:DMKDMK Pharmaceuticals Corporation
25/10/202323h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMKDMK Pharmaceuticals Corporation
25/10/202323h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DMKDMK Pharmaceuticals Corporation
20/10/202322h15GlobeNewswire Inc.DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:DMKDMK Pharmaceuticals Corporation
19/10/202323h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMKDMK Pharmaceuticals Corporation
 Showing the most relevant articles for your search:NASDAQ:DMK

Kürzlich von Ihnen besucht